Literature DB >> 9049856

Supratentorial gliomas: a comparative study by grade and histologic type.

E G Shaw1, B W Scheithauer, J R O'Fallon.   

Abstract

PURPOSE: To try and identify biologic differences based on tumor grade and histologic type between the major classes of glial tumors, including low-grade diffuse fibrillary and pilocytic astrocytomas, oligodendrogliomas, and mixed oligo-astrocytomas and high-grade diffuse fibrillary astrocytomas, oligodendrogliomas and mixed oligo-astrocytomas.
METHODS: Utilizing the St. Anne-Mayo (SAM) grading system, the incidence, patient characteristics, and survivals of 196 patients with low-grade (SAM grade 1 + 2) and 318 patients with high-grade (SAM 3 + 4) supratentorial tumors were compared.
RESULTS: Among low-grade tumors, most favorable were 5- and 10-year survival rates for patients with pilocytic astrocytomas, which were 85% and 79%, respectively. Median survival and 5- and 10-year survival rates for the other low-grade tumors were lower, and were proportionately improved by the presence of an oligodendroglial component: diffuse fibrillary astrocytomas-4.7 years, 46%, and 17%, oligodendroglioma-9.8 years, 73%, and 49%; and mixed oligo-astrocytoma-7.1 years, 63%, and 33%, respectively. For high-grade tumors, patients with either oligodendrogliomas or mixed oligo-astrocytomas had comparable favorable survivals in comparison to diffuse fibrillary astrocytomas. Median survivals and 5- and 10-year survival rates were 4.5 years, 45%, and 15% for the oligodendrogliomas and mixed oligo-astrocytomas versus 0.8 years, 3%, and 0% for the diffuse fibrillary astrocytomas, respectively.
CONCLUSION: These survival data suggest that both low-grade and high-grade supratentorial gliomas have outcomes which are highly dependent upon histologic type.

Entities:  

Mesh:

Year:  1997        PMID: 9049856     DOI: 10.1023/a:1005715703598

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  17 in total

1.  Supratentorial anaplastic gliomas in adults. The prognostic importance of extent of resection and prior low-grade glioma.

Authors:  M J Winger; D R Macdonald; J G Cairncross
Journal:  J Neurosurg       Date:  1989-10       Impact factor: 5.115

2.  Radiation therapy in the management of low-grade supratentorial astrocytomas.

Authors:  E G Shaw; C Daumas-Duport; B W Scheithauer; D T Gilbertson; J R O'Fallon; J D Earle; E R Laws; H Okazaki
Journal:  J Neurosurg       Date:  1989-06       Impact factor: 5.115

3.  Mixed gliomas.

Authors:  M N Hart; C K Petito; K M Earle
Journal:  Cancer       Date:  1974-01       Impact factor: 6.860

4.  Mixed gliomas. Their clinical course and results of surgery.

Authors:  D Jaskólsky; M Zawirski; W Papierz; Z Kotwica
Journal:  Zentralbl Neurochir       Date:  1987

5.  Grading of astrocytomas. A simple and reproducible method.

Authors:  C Daumas-Duport; B Scheithauer; J O'Fallon; P Kelly
Journal:  Cancer       Date:  1988-11-15       Impact factor: 6.860

6.  Correlates of survival and the Daumas-Duport grading system for astrocytomas.

Authors:  T S Kim; A L Halliday; E T Hedley-Whyte; K Convery
Journal:  J Neurosurg       Date:  1991-01       Impact factor: 5.115

7.  Oligodendrogliomas: the Mayo Clinic experience.

Authors:  E G Shaw; B W Scheithauer; J R O'Fallon; H D Tazelaar; D H Davis
Journal:  J Neurosurg       Date:  1992-03       Impact factor: 5.115

8.  Oligodendroglioma. An analysis of the value of radiation therapy.

Authors:  D E Bullard; C E Rawlings; B Phillips; E B Cox; S C Schold; P Burger; E C Halperin
Journal:  Cancer       Date:  1987-11-01       Impact factor: 6.860

9.  Successful chemotherapy for recurrent malignant oligodendroglioma.

Authors:  J G Cairncross; D R Macdonald
Journal:  Ann Neurol       Date:  1988-04       Impact factor: 10.422

10.  Mixed oligoastrocytomas: a survival and prognostic factor analysis.

Authors:  E G Shaw; B W Scheithauer; J R O'Fallon; D H Davis
Journal:  Neurosurgery       Date:  1994-04       Impact factor: 4.654

View more
  25 in total

1.  Diagnosis of malignant glioma: role of neuropathology.

Authors:  Daniel J Brat; Richard A Prayson; Timothy C Ryken; Jeffrey J Olson
Journal:  J Neurooncol       Date:  2008-08-20       Impact factor: 4.130

2.  Wide Range of Clinical Outcomes in Patients with Gliomatosis Cerebri Growth Pattern: A Clinical, Radiographic, and Histopathologic Study.

Authors:  K Ina Ly; Derek H Oakley; Alexander B Pine; Matthew P Frosch; Sy Han Chiou; Rebecca A Betensky; Stuart R Pomerantz; Fred H Hochberg; Tracy T Batchelor; Daniel P Cahill; Jorg Dietrich
Journal:  Oncologist       Date:  2018-08-10

3.  CXCL12 expression is predictive of a shorter time to tumor progression in low-grade glioma: a single-institution study in 50 patients.

Authors:  A Salmaggi; M Gelati; B Pollo; C Marras; A Silvani; M R Balestrini; M Eoli; L Fariselli; G Broggi; A Boiardi
Journal:  J Neurooncol       Date:  2005-09       Impact factor: 4.130

Review 4.  Low-grade gliomas: the debate continues.

Authors:  Paul D Brown
Journal:  Curr Oncol Rep       Date:  2006-01       Impact factor: 5.075

Review 5.  Complications and expected outcome of glioma surgery.

Authors:  K P Vives; J M Piepmeier
Journal:  J Neurooncol       Date:  1999-05       Impact factor: 4.130

6.  Clinical prognostic factors of adjuvant radiation therapy for low-grade gliomas: results of 10 years survival.

Authors:  Vildan Kaya; Melek Gamze Aksu; Aylin Fidan Korcum; Beyza Ozdemir; Yiğit Ceçen; Bora Sindir; Mine Genç
Journal:  Int J Clin Exp Med       Date:  2014-05-15

Review 7.  Low-grade gliomas.

Authors:  Jimmy Ruiz; Glenn J Lesser
Journal:  Curr Treat Options Oncol       Date:  2009-04-19

Review 8.  The role of chemotherapy for pure and mixed anaplastic oligodendroglial tumors.

Authors:  Erin M Dunbar
Journal:  Curr Treat Options Oncol       Date:  2009-04-18

9.  Low-grade gliomas in older patients: long-term follow-up from Mayo Clinic.

Authors:  David A Schomas; Nadia N Laack; Paul D Brown
Journal:  Cancer       Date:  2009-09-01       Impact factor: 6.860

10.  Prognostic value of choline and creatine in WHO grade II gliomas.

Authors:  Elke Hattingen; Peter Raab; Kea Franz; Heiner Lanfermann; Matthias Setzer; Rüdiger Gerlach; Friedhelm E Zanella; Ulrich Pilatus
Journal:  Neuroradiology       Date:  2008-06-04       Impact factor: 2.804

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.